Tonje Amb Aksnes (f. 1973) er ph.d. og spesialist i kardiologi og indremedisin og medlem av styret i Norsk hypertensjonsforening. Hun er for tiden i permisjon fra Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål.
Forfatter har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Hun har mottatt foredragshonorar/reisestøtte fra AstraZeneca, MSD, Novartis og Pfizer.
Aud Høieggen (f. 1956) er spesialist i indremedisin og nyresykdommer, overlege ved nyremedisinsk avdeling, Oslo universitetssykehus, Ullevål, og førsteamanuensis ved Institutt for klinisk medisin, Universitetet i Oslo.
Forfatter har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Hun har mottatt foredragshonorar fra AstraZeneca, Novartis, Amgen og St. Jude Medical.
Sverre Erik Kjeldsen (f. 1953) er indremedisiner og kardiolog. Han er professor og seksjonsoverlege ved Hjertemedisinsk avdeling, Oslo universitetssykehus, Ullevål.
Forfatter har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Han har mottatt konsultasjonshonorar/forskningsstøtte/foredragshonorar fra Bayer, Medtronic, Serodus, Takeda, AstraZeneca, Pronova, MSD.
Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095 – 128. [PubMed] [CrossRef]
2.
Gu Q, Burt VL, Dillon CF et al. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105 – 14. [PubMed] [CrossRef]
3.
Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995 – 1003. [PubMed] [CrossRef]
4.
Kjeldsen SE, Dahlöf B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491 – 8. [PubMed] [CrossRef]
5.
Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712 – 9. [PubMed] [CrossRef]
6.
Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022 – 31. [PubMed] [CrossRef]
7.
Schmieder RE, Kjeldsen SE, Julius S et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403 – 11. [PubMed] [CrossRef]
8.
Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895 – 906. [PubMed] [CrossRef]
9.
Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417 – 28. [PubMed] [CrossRef]
10.
Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Press 2013; 22: 193 – 278. [PubMed] [CrossRef]
11.
Ma L, Wang W, Zhao Y et al. Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. Am J Cardiovasc Drugs 2012; 12: 137 – 42. [PubMed] [CrossRef]
12.
Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635 – 701. [PubMed] [CrossRef]
13.
Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405 – 12. [PubMed] [CrossRef]
14.
Östergren J, Poulter NR, Sever PS et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertens 2008; 26: 2103 – 11. [PubMed] [CrossRef]
15.
Weber MA, Bakris GL, Jamerson K et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56: 77 – 85. [PubMed] [CrossRef]
16.
Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49: 12 – 26. [PubMed] [CrossRef]
17.
Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547 – 59. [PubMed] [CrossRef]
18.
Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547 – 53. [PubMed] [CrossRef]
19.
Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173 – 81. [PubMed] [CrossRef]
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.